Find Clinical Trial
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
← Back
| Study Phase |
Phase 1-2 |
| Therapeutic Area |
Cancers |
| Indication | Advanced Non-small Cell Lung Cancer |
| Sponsor | Institut de Recherches Internationales Servier (IRIS) |
| Active substance/ Medical device |
Cemiplimab (anti-PD1 antibody), S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), S095029 (anti-NKG2A antibody) |
| Active Substance Code | S95018, S95024, S95029, cemiplimab |
| Protocol Code | SPLFIO-174 |
| NCT Code | NCT06162572 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
